Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Rhea-AI Summary

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced interim results from its ongoing in-vivo study of RCC-33, a drug candidate for colorectal cancer, revealing a 27% reduction in tumor volume after 12 days of treatment in nude mice compared to the control group. This significant result, with a p-value of 0.022, marks a promising development towards potential FDA approval. The study was initiated alongside the objective of improving survival rates for colorectal cancer patients, which currently stands at 67% for five-year survival with existing treatments.

Positive

• 27% reduction in tumor volume observed in mice treated with RCC-33.
• Statistically significant results with a p-value of 0.022.
• Potential pathway towards FDA approval for RCC-33.

Negative

• None.

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cancer in nude-mice. The interim results show a 27% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice. Both groups were inoculated with colorectal cancer cells. Daily doses of intraperitoneal (IP) delivery of RCC-33 or sham were initiated on day 5. Differences in tumor volume between the two groups were first observed after 5 days of treatment (day 10). Interim results of a 27% reduction in tumor volume were recorded after 12 days of treatment (day 17), with p-value=0.022. Study is ongoing.

Gabriel Yariv, Cannabics Pharmaceuticals' President and COO said: "Developing innovative formulations to combat colorectal cancer is a worthy cause. Colorectal cancer is the third most diagnosed cancer worldwide and the second most lethal. That said, 67% of colorectal cancer patients undergoing currently available treatments survive for 5 years or longer. Accordingly, our objective with RCC-33 is to be able to demonstrate its efficacy and enter an official FDA track, eventually reaching a position where we can potentially help a large group of people get better and live longer; this is our ultimate goal and today marks an important step in the right direction."

Dr. Eyal Ballan, Cannabics Pharmaceuticals Co-founder and CTO said: "Today's interim results mark an important milestone for the company. Seeing our formulation cause attenuation in tumor growth, in-vivo, and already within 12 days of treatment, is a clear indicator and an encouragement for us to continue with our focus and efforts in the direction we chose and believe in."

About Cannabics Pharmaceuticals:

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicines. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed January 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1-(877)-424-2429
info@Cannabics.com
http://www.Cannabics.com

Related Links
https://www.cannabics.com

SOURCE Cannabics Pharmaceuticals Inc.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-interim-in-vivo-study-results-show-a-27-lower-tumor-volume-in-mice-treated-with-companys-proprietary-drug-candidate-for-colorectal-cancer-301221349.html

SOURCE Cannabics Pharmaceuticals Inc.

FAQ

What are the interim results of Cannabics Pharmaceuticals' study on RCC-33?

The interim results show a 27% reduction in tumor volume in mice treated with RCC-33 compared to control mice, with a p-value of 0.022.

When were the interim results of the RCC-33 study announced?

The interim results were announced on February 3, 2021.

What is the significance of the RCC-33 drug candidate?

RCC-33 aims to provide a new treatment option for colorectal cancer, potentially improving survival rates beyond the current 67% five-year survival rate.

Is Cannabics Pharmaceuticals planning to apply for FDA approval for RCC-33?

Yes, Cannabics Pharmaceuticals intends to demonstrate RCC-33's efficacy to enter the official FDA approval process.

What is the stock symbol for Cannabics Pharmaceuticals?

The stock symbol for Cannabics Pharmaceuticals is CNBX.